$Viking 治疗.US VKTX 表示，该药物的一期临床试验重点评估了其安全性，并在为期 28 天的治疗过程中，患者体重平均减轻了 5.3%，这一成果显著超出市场预期。值得一提的是，该药物在临床试验中未表现出任何安全问题，且大多数副作用轻微，这使其相较于当前市场上的注射剂领导者如诺和诺德（NVO）和礼来（LLY）具有显著优势。
Tesla Return Rate
CommemorativeThe copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Like